Clinical Trial Update: Effect of LY333531 on Vascular and Neural Functions [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ruboxistaurin (LY333531) on vascular and neural functions in diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• ruboxistaurin (LY333531) (ruboxistaurin)

Snippet

Sponsor: Chromaderm, Inc. | Conditions: Diabetes Mellitus | Phase 2 | Status: COMPLETED